Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270942 · ClinicalTrials.gov registry record · Phase 2
At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)
A Phase 2 study, sponsored by Provention Bio, a Sanofi Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT04270942 is a Phase 2 study that has completed, run by Provention Bio, a Sanofi Company. The registered enrollment target is 6 participants.
The verdict
NCT04270942, a Phase 2 study, has completed, sponsored by Provention Bio, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatment within one year of diagnosis of clinical type 1 diabetes.
Interventions
- DRUG teplizumab 1 mg/mL
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2020-02-26 |
| Est. Completion | 2024-01-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04270942
The ClinicalTrials.gov registry entry for NCT04270942 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Provention Bio, a Sanofi Company, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which teplizumab 1 mg/mL is the first listed.
NCT04270942 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04270942 about?
NCT04270942 is a clinical study titled "At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)". This study was an extension of the NIH-sponsored At-Risk (TN-10) type 1 diabetes study (NCT 01030861). Teplizumab-treated and placebo-treated participants in the NIH trial who developed clinical type 1 diabetes after the conclusion of that trial, were eligible to enroll and receive teplizumab treatm...
What is the current status of trial NCT04270942?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2020-02-26. Estimated completion is 2024-01-22.
What interventions are being tested in trial NCT04270942?
The interventions under investigation include: teplizumab 1 mg/mL (DRUG).
Who is sponsoring clinical trial NCT04270942?
This trial is sponsored by Provention Bio, a Sanofi Company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.